News | Focused Ultrasound Therapy | October 30, 2020

Two Landmark Studies Advance Focused Ultrasound Treatment for Parkinson's Disease

These two studies are a critical first step in using focused ultrasound to treat the underlying causes of Parkinson's

José Obeso, MD, PhD, (left) of of the Centro Integral de Neurociencias (HM CINAC) in Madrid and Nir Lipsman, MD, PhD, (right) of Sunnybrook Health Sciences Centre in Toronto. Each doctor is leading a clinical trial using focused ultrasound to target the striatum in patients with Parkinson's disease.

José Obeso, MD, PhD, (left) of of the Centro Integral de Neurociencias (HM CINAC) in Madrid and Nir Lipsman, MD, PhD, (right) of Sunnybrook Health Sciences Centre in Toronto. Each doctor is leading a clinical trial using focused ultrasound to target the striatum in patients with Parkinson's disease.

October 30, 2020 — A team of researchers in Madrid, Spain, and another team in Toronto, Canada, are the first in the world to use focused ultrasound technology to target a new area of the brain in patients with Parkinson's disease and potentially curb, or even reverse, its progression.

Both ongoing clinical trials focus on the striatum, a hub of neurons deep in the brain that is one of the principal components of the basal ganglia – an area that plays a central role in facilitating voluntary movement. The severity of movement-related symptoms of Parkinson's is associated with the neurodegeneration of dopaminergic nigrostriatal projection.

Focused ultrasound has previously gained international regulatory approvals for the treatment of tremor-dominant Parkinson's, including US Food and Drug Administration approval in 2018. The trials in Madrid and Toronto represent the first application of the technology with the goal of stopping the progression of Parkinson's, rather than merely treating the symptoms.

A hallmark of Parkinson's disease is the abnormal accumulation of a protein called alpha-synuclein, which leads to unhealthy brain cells and neurodegeneration. Promising treatments to reduce alpha-synuclein accumulation, however, have been limited by their inability to cross the blood-brain barrier (BBB) and reach the target.

José Obeso, M.D., Ph.D., of the Centro Integral de Neurociencias (HM CINAC) in Madrid recently led the first clinical trial in the world to use focused ultrasound to temporarily and reversibly open the BBB in the putamen region of the striatum of Parkinson's patients. To date, seven patients have been treated.

"Focused ultrasound opening of the blood-brain barrier provides a unique opportunity for early intervention to treat neurodegenerative disorders, such as Parkinson's," said Obeso. "Striatal opening, in particular, could be readily applied to treat Parkinson's patients early in the evolution of the disease. This could be a revolutionary advance."

In another groundbreaking clinical trial, Nir Lipsman, M.D., Ph.D., is co-leading a team of researchers at Sunnybrook Health Sciences Centre and University Health Network in Toronto who are the first in the world to use focused ultrasound to deliver a therapeutic directly to the striatum in patients with Parkinson's. The team is using low-intensity ultrasound waves to cause a temporary opening in the BBB, which allows access to the striatum and the direct delivery of an enzyme replacement therapy (glucocerebrosidase). To date, three patients have been treated in this study.

"The goal of this trial is to examine the safety of temporarily opening the blood-brain barrier in key motor regions known to be implicated in Parkinson's disease and delivering promising therapeutics directly to these areas of the brain," said Lipsman, Director of Sunnybrook's Harquail Centre for Neuromodulation.

Pat Wilson, the first patient in the Sunnybrook study said, "I hope that by taking part in this clinical trial, I can help make a difference. My father had Parkinson's, and I saw the difficulties he faced. I am living with the challenges of this condition, and I hope that this study can help in finding a treatment to help others with Parkinson's in the future."

Both ongoing trials are using Insightec's Exablate Neuro device, and the trial in Toronto is funded in part by the Focused Ultrasound Foundation.

"Focused ultrasound is a revolutionary, noninvasive technology that has the potential to transform the treatment of Parkinson's disease and other neurodegenerative disorders," said Neal F. Kassell, MD, Chairman and Founder of the Focused Ultrasound Foundation. "These two studies are a critical first step in using focused ultrasound to treat the underlying causes of Parkinson's disease."

For more information: http://www.fusfoundation.org

Related Content

Images, or a digital twin mitral valve of a patient, created from cardiac ultrasound that were used to perform a virtual surgical procedure to test how the intervention would impact the patient prior to actually performing the procedure. The right image shows color coding for sheer stresses on the valve leaflets before and after the virtual surgery. The left image shows the model quantitation of leaflet coaptation at peak systole prior to the the virtual surgery.

Images, or a digital twin mitral valve of a patient, created from cardiac ultrasound that were used to perform a virtual surgical procedure to test how the intervention would impact the patient prior to actually performing the procedure. The right image shows color coding for sheer stresses on the valve leaflets before and after the virtual surgery. The left image shows the model quantitation of leaflet coaptation at peak systole prior to the the virtual surgery. Read the original article in Plos One.

Feature | Ultrasound Imaging | July 28, 2021
Outside of medicine, computer-generated virtual twins of real machines like cars or airplanes have been used in engin
If you plan to attend HIMSS21 Aug. 9-13 in Las Vegas, be sure to note that due to health and safety updates, masks will now be required for attendees and exhibitors.

Getty Images

News | HIMSS | July 28, 2021
July 28, 2021 —If you plan to attend HIMSS21 Aug.
The FLASH Effect significantly improves the therapeutic ratio for curing cancer

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

News | Radiation Oncology | July 28, 2021
July 28, 2021 — IntraOp Medical Corporation announced that ...
Researchers from the School of Biomedical Engineering & Imaging Sciences at King's College London have automated brain MRI image labeling, needed to teach machine learning image recognition models, by deriving important labels from radiology reports and accurately assigning them to the corresponding MRI examinations

Getty Images

News | Magnetic Resonance Imaging (MRI) | July 28, 2021
July 28, 2021 — Researchers from the School of Biomedical Engineering & Imaging Sciences at...
A new Harvey L. Neiman Health Policy Institute study found that patients paid 12% of the costs of secondary imaging interpretation out-of-pocket. Such secondary interpretations are increasingly performed for complex patients, but patients’ liabilities and paid out-of-pocket costs were not previously known.

Getty Images

News | Radiology Imaging | July 28, 2021
July 28, 2021 — A new Harvey L.